TransCode Therapeutics, Inc. (RNAZ) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

TransCode Therapeutics, Inc. (RNAZ) Healthcare & Pipeline Overview

TransCode Therapeutics, Inc. is a preclinical-stage biopharmaceutical company specializing in RNA-based therapies and diagnostics for metastatic cancer. Their innovative pipeline, including TTX-MC138 and other siRNA and mRNA-based programs, aims to address unmet needs in cancer treatment by targeting key pathways and the tumor microenvironment.

What Is the Investment Thesis for RNAZ?

TransCode Therapeutics presents a high-risk, high-reward investment opportunity given its focus on novel RNA-based therapies for metastatic cancer. The company's lead candidate, TTX-MC138, and other preclinical programs offer potential for significant breakthroughs in cancer treatment. However, the company's early stage of development and limited financial resources pose substantial risks. Key value drivers include successful preclinical development and advancement of TTX-MC138 into clinical trials, positive clinical data from its other pipeline programs, and potential partnerships or collaborations with larger pharmaceutical companies. The company's market capitalization of $3.14M reflects the speculative nature of the investment. The company's P/E ratio is -0.30, indicating that the company is not currently profitable. The beta of 1.54 suggests that the stock is more volatile than the market. The absence of a dividend reflects the company's focus on reinvesting capital into research and development. The investment thesis hinges on the successful execution of its preclinical programs and the ability to secure funding to advance its pipeline.

Based on FMP financials and quantitative analysis

RNAZ Key Highlights

TransCode Therapeutics is focused on RNA-based therapies for metastatic cancer, a significant area of unmet medical need.

• Lead therapeutic candidate, TTX-MC138, is in preclinical development for the treatment of metastatic cancer.
• The company has a pipeline of preclinical programs targeting various cancer-related pathways, including PD-L1 and LIN28B.
• TransCode's cancer agnostic programs include TTX-RIGA, TTX-CRISPR, and TTX-mRNA, offering potential for broad application across different cancer types.
• The company's market capitalization is $0.01 billion as of 2026-03-15, reflecting its early stage of development and speculative nature.

Who Are RNAZ's Competitors?

RNAZ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RNAZ's Key Strengths?

Proprietary RNA-based technology platform.

• Focus on metastatic cancer, a significant area of unmet medical need.
• Pipeline of preclinical programs targeting various cancer-related pathways.
• Experienced management team with expertise in RNA therapeutics.

What Are RNAZ's Weaknesses?

Early stage of development with no approved products.

• Limited financial resources.
• High risk of failure in preclinical and clinical development.
• Dependence on key personnel and intellectual property.

What Could Drive RNAZ Stock Higher?

Preclinical data releases for TTX-MC138 and other pipeline programs.

• IND filing for TTX-MC138.
• Initiation of clinical trials for TTX-MC138.
• Strategic partnerships and collaborations with larger pharmaceutical companies.
• Securing additional funding to advance pipeline programs.

What Are the Key Risks for RNAZ?

Financial-distress signal — its Altman Z-Score of -1.09 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-99.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
• Failure of preclinical programs to advance into clinical trials.
• Negative clinical trial results.
• Competition from other biotechnology and pharmaceutical companies.
• Regulatory hurdles and delays.
• Limited financial resources.

What Are the Growth Opportunities for RNAZ?

• Advancement of TTX-MC138 into Clinical Trials: TransCode's primary growth opportunity lies in successfully advancing its lead therapeutic candidate, TTX-MC138, into clinical trials. Positive preclinical data and successful IND filing could lead to significant investor interest and potential partnerships. The market for metastatic cancer therapies is substantial, with a global market size estimated at billions of dollars. Timeline: 2027-2028.
• Development of TTX-siPDL1: The development of TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), represents another significant growth opportunity for TransCode. PD-L1 is a key target in cancer immunotherapy, and TTX-siPDL1 has the potential to enhance the immune response against cancer cells. The market for PD-L1 inhibitors is large and growing, with several approved therapies already on the market. Timeline: 2028-2029.
• Expansion of Cancer Agnostic Programs: TransCode's cancer agnostic programs, including TTX-RIGA, TTX-CRISPR, and TTX-mRNA, offer potential for broad application across different cancer types. These programs target fundamental mechanisms of cancer development and progression, and could lead to the development of new therapies for a wide range of cancers. The market for cancer agnostic therapies is potentially very large, as it could address unmet needs in multiple cancer types. Timeline: 2029-2030.
• Strategic Partnerships and Collaborations: TransCode could pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline programs. Partnerships could provide access to additional funding, expertise, and resources. The pharmaceutical industry is actively seeking innovative technologies and therapies, and TransCode's RNA-based platform could be an attractive target for partnerships. Timeline: Ongoing.
• Development of Diagnostic Assays: TransCode could develop diagnostic assays to identify patients who are most likely to respond to its therapies. Diagnostic assays could improve patient selection and treatment outcomes, and could also generate revenue for the company. The market for cancer diagnostics is growing, driven by the increasing use of personalized medicine. Timeline: 2028-2030.

What Threats Does RNAZ Face?

• Competition from other biotechnology and pharmaceutical companies.
• Regulatory hurdles and delays.
• Patent challenges and intellectual property infringement.
• Economic downturn and reduced access to capital.

What Are RNAZ's Competitive Advantages?

• Proprietary RNA-based technology platform.
• Focus on metastatic cancer, a significant area of unmet medical need.
• Pipeline of preclinical programs targeting various cancer-related pathways.

What Does RNAZ Do?

TransCode Therapeutics, Inc., founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to developing and commercializing innovative RNA-based therapeutics and diagnostics for the treatment and identification of metastatic disease. The company's mission is to transform cancer treatment by targeting the underlying mechanisms that drive metastasis. Their lead therapeutic candidate, TTX-MC138, is currently in the preclinical stage and is designed to treat metastatic cancer by targeting microRNA-10b, which is overexpressed in many metastatic cancers. In addition to TTX-MC138, TransCode has a pipeline of preclinical programs, including TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), designed to enhance the immune response against cancer cells. TTX-siLIN28B, another siRNA-based program, targets the RNA-binding protein LIN28B, which is implicated in cancer development and progression. TransCode's cancer agnostic programs include TTX-RIGA, an RNA-based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company is focused on advancing these programs through preclinical development and into clinical trials, with the goal of providing new and effective treatment options for patients with metastatic cancer. TransCode operates in the competitive biotechnology landscape, striving to differentiate itself through its focus on RNA-based therapies and diagnostics for metastatic disease.

What Products and Services Does RNAZ Offer?

• Develop RNA-based therapeutics for metastatic cancer.
• Focus on identifying and treating metastatic disease.
• Develop TTX-MC138, a preclinical stage product for metastatic cancer treatment.
• Create siRNA-based modulators of programmed death-ligand 1 (TTX-siPDL1).
• Develop siRNA-based inhibitors of RNA-binding protein LIN28B (TTX-siLIN28B).
• Develop RNA-based agonists of the RIG-I-driven immune response (TTX-RIGA).
• Create CRISPR/Cas9-based therapy platforms for cancer-causing genes (TTX-CRISPR).
• Develop mRNA-based platforms for cancer vaccines (TTX-mRNA).

How Does RNAZ Make Money?

• Develop and commercialize RNA-based therapeutics and diagnostics.
• Focus on treating and identifying metastatic disease.
• Generate revenue through partnerships, licensing agreements, and eventual product sales.

What Industry Does RNAZ Operate In?

TransCode Therapeutics operates within the competitive biotechnology industry, which is characterized by rapid innovation, high risk, and significant potential for reward. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing incidence of cancer. The industry is highly competitive, with numerous companies developing new therapies and diagnostics for cancer. TransCode differentiates itself through its focus on RNA-based therapies and diagnostics for metastatic disease. Competitors include companies developing similar RNA-based therapeutics, as well as companies developing other types of cancer therapies, such as chemotherapy, immunotherapy, and targeted therapies. The biotechnology industry is subject to significant regulatory oversight, and companies must navigate a complex regulatory landscape to bring new products to market.

Who Are RNAZ's Key Customers?

• Patients with metastatic cancer.
• Healthcare providers who treat cancer patients.
• Pharmaceutical companies seeking to license or acquire new cancer therapies.

How TransCode Therapeutics, Inc. Is Valued

TransCode Therapeutics, Inc. carries a market capitalization of $3.14M, placing it in the micro-cap category. Relative to its peer group, RNAZ's quantitative score of 27/100 is roughly in line with the peer average of 37/100.

Company Profile

TransCode Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Philippe Calais. RNAZ has traded publicly since 2021.

Return on equity for TransCode Therapeutics, Inc. stands at -99.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -25.7%, showing how much profit it generates from its asset base. A current ratio of 3.11 indicates the company holds enough short-term assets to cover its near-term obligations.

TransCode Therapeutics, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.09 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project TransCode Therapeutics, Inc. revenue of about $500K for fiscal 2026, with EPS near $-8.96.

Over the past six months, TransCode Therapeutics, Inc. insiders filed 4 SEC Form 4 transactions — 2 sales and 2 purchases. On net that is roughly 13.8M shares acquired (about $1K) — insiders putting money in tends to read as conviction.

RNAZ Financials

RNAZ Latest News

RNAZ Analyst Consensus

RNAZ MoonshotScore

What Investors Ask About TransCode Therapeutics, Inc. (RNAZ) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources